WO2007097452A1 - Emballage-coque à usage médical - Google Patents

Emballage-coque à usage médical Download PDF

Info

Publication number
WO2007097452A1
WO2007097452A1 PCT/JP2007/053545 JP2007053545W WO2007097452A1 WO 2007097452 A1 WO2007097452 A1 WO 2007097452A1 JP 2007053545 W JP2007053545 W JP 2007053545W WO 2007097452 A1 WO2007097452 A1 WO 2007097452A1
Authority
WO
WIPO (PCT)
Prior art keywords
space
methyl
odor
sheet material
oxo
Prior art date
Application number
PCT/JP2007/053545
Other languages
English (en)
Japanese (ja)
Inventor
Koji Nonomura
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of WO2007097452A1 publication Critical patent/WO2007097452A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments
    • B65D75/328—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments the compartments being interconnected, e.g. by small channels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants

Definitions

  • the present invention relates to a pharmaceutical package with reduced unpleasant odor.
  • olmesartan medoxomil which is a monocyclic imidazole derivative clinically used as a therapeutic drug for hypertension
  • Patent Document 1 Japanese Patent Laid-Open No. 5-78328
  • Decomposition is a method of decomposing substances that cause odors, including ozone decomposition, catalyst decomposition, and chemical decomposition.
  • the adsorption method is a method of adsorbing substances that cause odors, such as adsorption with activated carbon or adsorption to an electric field with high voltage applied.
  • the masking method uses a fragrance or the like to make an unpleasant odor feel.
  • olmesartan medoxomil In the preparation of olmesartan medoxomil, a pharmaceutical package in which tablets or capsules containing olmesartan medoxomil are packaged in a bottle together with a desiccant, or a blister package containing a plurality of preparations containing olmesartan medoxomil in combination with an aluminum- A medicine package stored in a bag made of rubber is used.
  • Blister packaging is packaging in which a packaging film in which a concave portion for accommodating an object to be packaged is formed is heat-sealed on a sheet material, and is widely used as packaging for pharmaceutical products.
  • Blister As a form of packaging, the first space for accommodating the first packaged article, the second space for accommodating the second packaged article, and the communication for communicating the first and second spaces with each other A form having a space is known, and by placing a pharmaceutical preparation as a first packaged article and a desiccant as a second packaged article, water around the preparation is removed, and Goods It is known to improve the quality (Patent Document 2: JP-A-4-71560).
  • Patent Document 1 Japanese Patent Laid-Open No. 5-78328
  • Patent Document 2 Japanese Patent Laid-Open No. 4-71560
  • Patent Document 3 International Publication No. 2005/080384
  • Patent Document 4 International Publication No. 2006/107062
  • a preparation containing Compound A or Compound B may emit a unique odor due to the compound having a medoxomil group in the molecule. Since the odor of the preparation containing Compound A or Compound B can be continuously generated by the gradual hydrolysis of medoxomil ester, a preparation that can effectively remove the odor that is continuously generated is necessary. It is said that.
  • the inventor comprises a sheet material and a packaging film sealed to the sheet material, and the first space, the second space, and the space between the sheet material and the film, First and second By using a package with a communication space that communicates the spaces with each other, placing a preparation containing a compound that emits an odor in the first space and placing a desiccant in the second space In addition, the inventors have found that the odor in the preparation is continuously reduced, and have completed the present invention.
  • the present invention provides:
  • a pharmaceutical package comprising a package, a solid preparation capable of producing an odor, and a desiccant, wherein the package comprises a sheet material and a packaging film sealed to the sheet material, and the sheet material
  • a first space, a second space, and a communication space for communicating the first and second spaces with each other are provided between the film and the film.
  • a solid preparation capable of producing an odor is placed in the first space
  • a pharmaceutical package characterized in that a desiccant is placed in the second space;
  • the pharmaceutical package according to the above (1), wherein the solid preparation capable of producing an odor comprises a compound having a (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl group;
  • a compound having a (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl group is converted to 2-ethoxy-1- ⁇ [2 '-(5-oxo-4,5- Dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl ⁇ -1 ⁇ -benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1, 3-dioxy Sole-4-yl) methyl or 2-cyclopropyl-1- ⁇ [2 '-(5-oxo-4,5-dihydro-1,2,4-oxazolazole-3-yl) biphenyl-4 -Yl] methyl ⁇ -1 ⁇ -benzimidazole-7-power rubonic acid (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl or a salt thereof according to the above (2) Pharmaceutical package;
  • the present invention relates to a method for reducing the odor of a solid preparation capable of producing an odor.
  • FIG. 1 is an enlarged cross-sectional view of one unit of a pharmaceutical package according to one embodiment of the present invention.
  • FIG. 2 is a plan view of an example of the pharmaceutical package of the present invention.
  • the pharmaceutical package of the present invention comprises a sheet material and a packaging film sealed to the sheet material, and a first space and a second space between the sheet material and the film. And a communication space that allows the first and second spaces to communicate with each other, and a solid preparation that can emit odor is disposed in the first space of the package, and the second space is provided. It is characterized by continuously reducing the odor of solid preparations that can generate odor by placing a desiccant on the surface.
  • the sheet material for example, a plastic material, a metal material (eg, aluminum) or the like is used.
  • a metal material eg, aluminum
  • an impermeable sheet metal material such as aluminum
  • the packaging film for example, a plastic material, a metal material (eg, aluminum, etc.) and the like are used.
  • a moisture-impermeable packaging film such as a metal material such as aluminum is used.
  • the packaging film includes a space (first space) for storing a solid preparation as a packaged object, a space (second space) for storing a desiccant, and these spaces. Communicate with each other It is preferable that the communication space is formed into a concave shape by molding, and the packaging film is sealed to the sheet material in a portion other than these spaces.
  • the communication space may be formed by connecting the first space and the second space without forming a concave shape and without heat-sealing.
  • the communication space is smaller in height and width than the first space and the second space so that the solid preparation and the desiccant do not move through the communication space. And smaller than the external dimensions of the desiccant.
  • the volume of the first space, the second space, and the communication space that allows the first and second spaces to communicate with each other is not limited as long as it is within a range where an odor reduction effect can be achieved.
  • the solid preparation and the desiccant may be partitioned by a packaging material or the like as long as the substance causing the odor can permeate.
  • the number of spaces (first spaces) for containing the solid preparation that communicate with the space (second space) for containing the desiccant is not limited, and one second space is used. On the other hand, a plurality of first spaces may communicate with each other.
  • Examples of the package that can be used in the present invention include International Publication No. 96/07601, Japanese Unexamined Patent Publication No. 62-182073, Japanese Unexamined Patent Publication No. 4-71560, and Japanese Design Registration No. 1258907. , Japanese Design Registration No. 1258908, Japanese Design Registration No. 1258909, Japanese Design Registration No. 1258910, Japanese Design Registration No. 1258911, Japanese Design Registration No. 1259336, Japanese Design Registration No. 1259337, Japanese Design Registration No. 1259338, Japanese Design Registration No. 1259339, Japanese Design Registration No. 1259340, Japanese Design Registration No. 125 9341, Japanese Design Registration No. 1259342, Japanese Design Registration No.
  • Japan Examples include the package or container described in the Design Registration No. 1259344, the Japanese Design Registration No. 1259345, the Japanese Design Registration No. 1259346, the Japanese Design Registration No. 1259347, and the Japanese Design Registration No. 1259348. It is done.
  • FIG. 1 is an enlarged cross-sectional view of a unit of a pharmaceutical package according to an embodiment of the present invention
  • FIG. 2 is a plan view of an example of a pharmaceutical package of the present invention.
  • the pharmaceutical package of the present invention includes a package 1, a solid preparation 4 capable of producing an odor, and a desiccant 6.
  • the package 1 is a sheet material 2 and a package sealed on the sheet material 2. With film 3 And a first space 5, a second space 7, and a communication space 8 for communicating the first and second spaces with each other are provided between the sheet material 2 and the film 3.
  • a solid preparation 4 capable of producing an odor is disposed in the first space 5 and a desiccant 6 is disposed in the second space 7.
  • the solid preparation capable of producing an odor according to the present invention may contain a compound that emits an odor per se, or may contain a compound that can emit an odor by decomposition.
  • the distinction that many compounds are difficult to distinguish between “a compound that itself produces an odor” or “a compound that can generate an odor by decomposition” has no particular meaning in the present invention. ⁇ (Hereinafter, “compounds that themselves generate odors” and “compounds that can generate odors by decomposition” are collectively referred to as “compounds that generate odors”).
  • Examples of compounds that can generate odor include compounds having a (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl group (so-called medoxomil group) in the molecule ( Examples include olmesartan medoxomil, compound A, and compound B).
  • medoxomil group examples include olmesartan medoxomil, compound A, and compound B.
  • Compounds with a medoxomil group in the molecule generate low-molecular 2,3 butanedione (also called diacetyl) by the gradual cleavage of the medoxomil ester, and this 2,3 butanedione is a substance that causes a specific odor. It is thought that there is.
  • Compound A is 2-ethoxy- 1- ⁇ [2 '-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl ⁇ -1 ⁇ -benzimidazole-7-
  • Carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl is also expressed as its salt.
  • Compound B is 2-cyclopropyl-1- ⁇ [2 '-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl ] Methyl ⁇ -1 ⁇ -benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl or its salt.
  • Compound A and Compound B can be produced by the method disclosed in International Publication No. 2005/080384 or International Publication No. 2006/107062, or a method analogous thereto.
  • the compound capable of producing an odor includes a case where it is a pharmacologically acceptable salt.
  • an inorganic base e.g., alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, transition metals such as zinc, iron and copper
  • organic bases e.g., trimethylamine, triethylamine, pyridine, picoline, tromethamine, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, t-butylamine, N, N, dibenzylethylenediamine Salts with organic amines such as min, basic amino acids such as arginine, lysine and ornithine).
  • the compound has a basic functional group, for example, a salt with inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, or acetic acid, phthalic acid, fumaric acid, oxalic acid.
  • salts with organic acids such as tartaric acid, maleic acid, succinic acid, succinic acid, methanesulfonic acid and p-toluenesulfonic acid.
  • solid preparations that can generate odors include solid preparations suitable for oral administration such as tablets, capsules, and pills.
  • the solid preparation can be produced by a method known per se (for example, the method described in the 14th revised Japanese Pharmacopoeia General Rules for Preparations).
  • the active ingredients and excipients eg lactose, sucrose, glucose, starch, corn starch, sucrose, microcrystalline cellulose, licorice powder, mannitol, sorbitol, sodium bicarbonate, calcium phosphate, calcium sulfate
  • Add the binder eg, hydroxypropylcellulose, hydroxypropylmethylcellulose, polybutylpyrrolidone, gelatin, starch, gum arabic, tragacanth, strength ruboxymethylcellulose, sodium alginate.
  • the active ingredients and additives such as sucrose, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc.
  • a binder solution concentration: about 0.5 to 70% (W / V)
  • sucrose hydroxypropylcellulose
  • hydroxypropylmethylcellulose etc.
  • capsules the above-mentioned granules and fine granules are filled into capsules such as gelatin or hydroxy-pyrumethyl cellulose, or active ingredients are excipients (eg, lactose, sucrose, glucose, starch, Sucrose, microcrystalline cellulose, licorice powder, mann-toluene, sodium hydrogen carbonate, calcium phosphate, calcium sulfate, etc.) and gelatin or hydroxypropyl methylcellulose capsules may be filled.
  • excipients eg, lactose, sucrose, glucose, starch, Sucrose, microcrystalline cellulose, licorice powder, mann-toluene, sodium hydrogen carbonate, calcium phosphate, calcium sulfate, etc.
  • gelatin or hydroxypropyl methylcellulose capsules may be filled.
  • the solid preparation may be coated with a coating agent for taste masking, enteric or sustained release.
  • the coating agent include hydroxypropenoremethinoresenorelose, ethinoresenorelose, hydroxymethinosesenolose, hydroxypropinolecellulose, polyoxyethylene glycol, Tween 80, pull nick F68, and senocellulose acetate phthalate. , Hydroxypropinoremethinolecellulose phthalate, hydroxymethylcellulose acetate succinate, Eudragit (Rohm, Germany, methacrylic acid / acrylic acid copolymer), etc. Shading agents such as titanium oxide and bengara as required May be used.
  • Drying agent used in the present invention includes activated carbon, calcium chloride, silicon dioxide (silica gel), a combination of acid-alumina and diacid-silicon (silica alumina), acid Alumina (activated alumina), natural or synthetic zeolite (molecular sieve 3A, 4A, 5A, 13X), alophen, clay, silica gel and activated carbon mixture, silica gel and clay mixture, silica alumina and activated carbon mixture, synthetic zeolite and A mixture of activated carbon, a mixture of alophen and activated carbon (for example, a mixture of alofen and activated carbon, or a mixture of alofen and activated carbon), or a pulp containing silica gel (for example, fine particles between paper fibers) (Silica gel mixed, silica gel wrapped in paper tube, etc.) and pulp containing salty calcium (For example, a paper-based material impregnated with liquid calcium chloride and dried and film coated), or a pulp containing al
  • Activated carbon refers to a large specific surface area and adsorption capacity produced from charcoal, palm, coal, etc. This is a porous carbonaceous material having a slag and used as an adsorbent, a catalyst carrier and the like.
  • the specific surface area is 800 to 1200 m 2 / g
  • the pore volume is 0.2 to 2 cm 3 / g
  • the pore diameter is preferably 1 to 4 nm.
  • the preferred composition is carbon, but a small amount of hydrogen, Oxygen and inorganic components may be included.
  • the chemical structure is basically graphite (graphite), but it is amorphous and may contain functional groups such as hydroxyl groups and quinone groups on the surface.
  • One of the above desiccants may be used alone, or two or more may be used in combination.
  • a synthetic zeolite that is high even under low humidity conditions, has a drying ability, and has excellent moldability is particularly preferable.
  • the shape of the desiccant can be appropriately selected according to the type of desiccant used.
  • the desiccant can be formed into pellets, plates, rods, tablets, etc. that are large enough not to move in the communication space and placed in the second space, or powder, granules, pellets
  • oxygen absorbents and carbon dioxide absorbents in the design of packaging for suitable breathable packaging materials, such as pharmaceuticals and foodstuffs, etc.
  • suitable breathable packaging materials such as pharmaceuticals and foodstuffs, etc.
  • What is wrapped in a well-known packaging material eg, porous membrane made of plastic sheet with pores, or non-woven fabric, Japanese paper, Western paper, Darashin paper, etc.
  • put in a caster is the second space Can be arranged.
  • the amount of the desiccant used in the present invention is an amount sufficient to remove a substance causing odor (for example, 2,3-butanedione), that is, an amount sufficient to suppress or reduce the odor.
  • a substance causing odor for example, 2,3-butanedione
  • the amount depends on the type and shape of the desiccant used, the distance from the solid preparation, the type or amount of the odorous compound, the dosage form, the volume of the first space and the second space, presence or It varies depending on the amount of odorous substances produced and the storage conditions of solid preparations.
  • the desiccant of the present invention when used in a space of about 2 ml capacity, about 10 mg to about 10 g, preferably about 50 mg to about 5 g, more preferably about 10 mg to about 3 g of desiccant can be contained.
  • compound a 7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl potassium salt (hereinafter referred to as compound a) was used.
  • Compound a granulated lactose (trade name: Tablet 80, Megre 'Japan Co., Ltd.), light anhydrous kaiic acid (trade name: Aerosil), and magnesium stearate were prepared to give the following formulation per capsule.
  • Formulation Al, A2 or A3 and synthetic zeolite (Molecular sieve 13X) (tablet, diameter 7 mm, thickness 3 mm, approx. L lOmg) in a blister space where a moisture-impermeable packaging film is heat-sealed on a moisture-impermeable sheet material ) Both.
  • a composite (laminate) material comprising three layers of an outermost layer polyamide polymer film, an inner layer aluminum foil, and an innermost layer polyvinyl chloride vinyl film is used.
  • An aluminum foil was used as a moisture-impermeable sheet material.
  • Carrier gas helium
  • the diacetyl concentration (g / mL) in the blister packaging was as shown in Tables 2 and 3 below.
  • the concentration of diacetyl which is one of the odor components, was significantly reduced under the conditions normally used for the stability test of pharmaceuticals, and a deodorizing maintenance effect was obtained.
  • the odor of a pharmaceutical preparation useful as a therapeutic agent for hypertension is reduced.
  • the product value as a pharmaceutical can be further increased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Composite Materials (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention concerne un emballage à usage médical, qui comprend un élément d'emballage (1), une préparation solide (4) tendant à dégager une mauvaise odeur, et un agent dessiccatif (6). L'emballage de l'invention se caractérise en ce que l'élément d'emballage (1) est composé d'un matériau en feuille (2) et d'une pellicule d'emballage (3) hermétiquement fixée au matériau en feuille (2); qu'entre le matériau en feuille (2) et la pellicule d'emballage (3) sont ménagés un premier espace (5), un deuxième espace (7) et un espace de communication (8) par lequel communiquent le premier et le deuxième espace (5, 7); et que la préparation solide (4) tendant à dégager une mauvaise odeur est disposée dans le premier espace (5) tandis que l'agent dessiccatif (6) est disposé dans le deuxième espace (7). On obtient ainsi un emballage à usage médical dans lequel la mauvaise odeur est réduite.
PCT/JP2007/053545 2006-02-27 2007-02-26 Emballage-coque à usage médical WO2007097452A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77668806P 2006-02-27 2006-02-27
US60/776,688 2006-02-27

Publications (1)

Publication Number Publication Date
WO2007097452A1 true WO2007097452A1 (fr) 2007-08-30

Family

ID=38437487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/053545 WO2007097452A1 (fr) 2006-02-27 2007-02-26 Emballage-coque à usage médical

Country Status (1)

Country Link
WO (1) WO2007097452A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041663A1 (fr) * 2006-09-25 2008-04-10 Takeda Pharmaceutical Company Limited Emballage médical
WO2010018777A1 (fr) * 2008-08-11 2010-02-18 第一三共株式会社 Procédé de lutte contre les mauvaises odeurs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0471560A (ja) * 1990-07-10 1992-03-06 Mect Corp 包装体
JP2005272451A (ja) * 2004-02-25 2005-10-06 Takeda Chem Ind Ltd ベンズイミダゾール誘導体およびその用途
WO2006107062A2 (fr) * 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Derive de benzimidazole et utilisation de celui-ci

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0471560A (ja) * 1990-07-10 1992-03-06 Mect Corp 包装体
JP2005272451A (ja) * 2004-02-25 2005-10-06 Takeda Chem Ind Ltd ベンズイミダゾール誘導体およびその用途
WO2006107062A2 (fr) * 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Derive de benzimidazole et utilisation de celui-ci

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041663A1 (fr) * 2006-09-25 2008-04-10 Takeda Pharmaceutical Company Limited Emballage médical
WO2010018777A1 (fr) * 2008-08-11 2010-02-18 第一三共株式会社 Procédé de lutte contre les mauvaises odeurs
JP2015017136A (ja) * 2008-08-11 2015-01-29 第一三共株式会社 におい抑制方法
JP5688799B2 (ja) * 2008-08-11 2015-03-25 第一三共株式会社 におい抑制方法

Similar Documents

Publication Publication Date Title
JP5047156B2 (ja) 医薬パッケージ
JP5340925B2 (ja) 医薬パッケージ
AU2003227691B2 (en) Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
JP6072778B2 (ja) フシジン酸を含む組成物およびそのためのパッケージ
JPWO2012029899A1 (ja) 包装体
JP5854571B2 (ja) におい抑制方法
JP5190159B1 (ja) 医薬
WO2007097452A1 (fr) Emballage-coque à usage médical
JP2007211005A (ja) 固形製剤用組成物および固形製剤
JP2014139256A (ja) 包装により安定保存された固形製剤
JP2009227658A (ja) アカルボースを含有する錠剤
JP6188091B2 (ja) メドキソミル基を有するプロドラッグを含有するフィルムコーティング製剤
JP2013224285A (ja) 医薬
JP2016222714A (ja) 医薬
JP4341835B2 (ja) カプセル剤の保存容器並びに保存方法
KR102693304B1 (ko) 빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재
JP2017081830A (ja) 固形製剤包装体、及び固形製剤の臭い除去方法
JP2019043880A (ja) 医薬組成物
JP2024023047A (ja) ビルダグリプチン含有医薬品
JP2014034574A (ja) 医薬
JP2004073377A (ja) 固形医薬組成物中の有効成分の安定化方法
JP2004075582A (ja) 固形医薬組成物に処方される有効成分以外の成分の安定化方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07737397

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP